After years of preparation, Eli Lilly is on the brink of launching a ... including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Eli Lilly sued four telehealth firms, but it is adopting a new legal strategy in its fight against compounded GLP-1s.